#pancreatic cancer — Friday, May 01, 2026 (1 items)
| 0 | ℹ |
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.
(nature.com)
|
Nature Medicine 2026-05-01 | #cancer #immunotherapy #biomarker #pancreatic cancer #parp inhibition |